Bio-Rad snaps up antibody manufacturer in €53M cash deal


Bio-Rad Laboratories ($BIO) has snapped up AbD Serotec, a division of MorphoSys AG, for about €53 million ($70 million) in cash.

The Hercules, CA-based Bio-Rad, which makes and sells life science research and clinical diagnostic products, says the deal delivers a leading antibody manufacturer, with more than "15,000 antibodies, kits, and accessories."

AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as other facilities in Germany and the U.S.

"We are pleased to have AbD Serotec join Bio-Rad," said Norman Schwartz, Bio-Rad president and CEO. "With AbD Serotec's comprehensive catalog of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA, and cell sorting."

- here's the press release

Related Article:
Bio-Rad founder dies, stock soars on sale spec